Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006

BMC Public Health

Volumn 12, Issue 1, 2012, Pages

  Rastam, Samer ^a,e   Al Ali, Radwan ^a   Maziak, Wasim ^a,b   Mzayek, Fawaz ^a,c   Fouad, Fouad M ^a   O'Flaherty, Martin ^d   Capewell, Simon ^d  

^a Syrian Centre for Tobacco Studies   (Syrian Arab Republic)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c UNIVERSITY OF MEMPHIS   (United States)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e SYRIAN CENTER FOR TOBACCO STUDIES   (Syrian Arab Republic)

Author keywords

Coronary heart disease; Modelling; Mortality

Indexed keywords

ADULT; AGED; ARTICLE; BIOLOGICAL MODEL; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; RISK FACTOR; RURAL POPULATION; STATISTICS; SYRIAN ARAB REPUBLIC; URBAN POPULATION;

ADULT; AGED; CORONARY DISEASE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; MODELS, CARDIOVASCULAR; MORTALITY; PREVALENCE; RISK FACTORS; RURAL POPULATION; SYRIA; URBAN POPULATION;

EID: 84865811412     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-12-754     Document Type: Article

References (64)

1. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Murray CJ, Lopez AD, Lancet 1997 349 9061 1269 1276 10.1016/S0140-6736(96)07493-4 9142060
2. World Health Organization, The global burden of disease: 2004 update 2008
3. World Health Organization, The World health report 2003: shaping the future WHO, Geneva, Switzerland 2003
4. Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Reddy KS, Public Health Nutr 2002 5 1A 231 237 12027289
5. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, Lancet 2006 367 9524 1747 1757 10.1016/S0140-6736(06)68770-9 16731270
6. Acute Myocardial Infarction in Isfahan, Iran: Hospitalization and 28th day case-fata;ity Rate. Sarrafzadegan N, Oveisgharan S, Toghianifar N, Hosseini S, Rabiei K, ARYA Atherosclerosis Journal 2009 5 3 132 137 Fall
7. EMRO, Cardiovascular Diseases - prevention and Control - EMRO technical paper Series 7, October 1998 [ http://www.emro.who.int/dsaf/dsa444.pdf ] 23105937
8. Cardiovascular health among adults in Syria: a model from developing countries. Maziak W, Rastam S, Mzayek F, Ward KD, Eissenberg T, Keil U, Ann Epidemiol 2007 17 9 713 720 10.1016/j.annepidem.2007.03.016 17553700
9. Emerging epidemic of cardiovascular disease in developing countries. Reddy KS, Yusuf S, Circulation 1998 97 6 596 601 10.1161/01.CIR.97.6.596 9494031
10. Reducing the growing burden of cardiovascular disease in the developing world. Gaziano TA, Health Aff (Millwood) 2007 26 1 13 24 10.1377/hlthaff.26.1.13
11. World Health Organization, WHO Global Health Observatory 2004 [ http://apps.who.int/ghodata/ ]
12. World Health Organization, WHO Statistical Information System 2006 [ http://www.who.int/whosis/mort/download/en/index.html ]
13. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Capewell S, Beaglehole R, Seddon M, McMurray J, Circulation 2000 102 13 1511 1516 10.1161/01.CIR.102.13.1511 11004141
14. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Critchley J, Liu J, Zhao D, Wei W, Capewell S, Circulation 2004 110 10 1236 1244 10.1161/01.CIR.0000140668.91896.AE 15337690
15. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Capewell S, Morrison C, McMurray J, Heart 1999 8 4 380 386
16. Central Bureau of Statistics, Central Bureau of Statistics 2011 [ http://www.cbssyr.org/index-EN.htm ]
17. United Nations, Department of economics and social affairs 2011 [ http://www.un.org/esa/population/ ]. Accessed on 27 January 2011
18. Mapping the health and environmental situation in informal zones in Aleppo, Syria: report from the Aleppo household survey. Maziak W, Ward KD, Mzayek F, Rastam S, Bachir ME, Fouad MF, Hammal F, Asfar T, Mock J, Nuwayhid I, et al. Int Arch Occup Environ Health 2005 78 7 547 558 10.1007/s00420-005-0625-7 15999277
19. The geometric mean of the age-specific death rates as a summary index of mortality. Schoen R, Demography 1970 7 3 317 324 10.2307/2060150 5524636
20. World Health Organization, Noncommunicable diseases. STEPwise surveillance. Syrian Arab Republic Report 2003 [ http://www.emro.who.int/ncd/ pdf/stepwise-syria.pdf ]
21. Modifiable cardiovascular risk factors among adults in Aleppo, Syria. Al Ali R, Rastam S, Fouad FM, Mzayek F, Maziak W, Int J Public Health 2011 56 6 653 62 10.1007/s00038-011-0278-0 21814848
22. Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation. Hikita H, Sato A, Nozato T, Kawashima T, Takahashi Y, Kuwahara T, Takahashi A, Scand Cardiovasc J 2009 43 5 298 303 10.1080/14017430902785493 19263268
23. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Horie H, Takahashi M, Minai K, Izumi M, Takaoka A, Nozawa M, Yokohama H, Fujita T, Sakamoto T, Kito O, et al. Circulation 1998 98 22 2377 2382 10.1161/01.CIR.98. 22.2377 9832481
24. Topol EJ, Califf RM, Vandormael M, Grines CL, George BS, Sanz ML, Wall T, O'Brien M, Schwaiger M, Aguirre FV, et al. Circulation 1992 85 6 2090 2099 10.1161/01.CIR.85.6.2090 1591828
25. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988 2 8607 349 360 2899772
26. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998 97 22 2202 2212 9631869
27. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 (7329 71 86 11786451
28. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD, J Am Coll Cardiol 2006 47 8 1576 1583 10.1016/j.jacc.2005.11.073 16630993
29. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. Anand SS, Yusuf S, JAMA 1999 282 21 2058 2067 10.1001/jama.282.21.2058 10591389
30. Optimal medical therapy with or without PCI for stable coronary disease. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, et al. N Engl J Med 2007 356 15 1503 1516 10.1056/NEJMoa070829 17387127
31. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de Werf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, et al. Lancet 2002 359 9302 189 198 10.1016/S0140-6736(02)07442-1 11812552
32. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, Lancet 2005 366 9497 1607 1621 16271642
33. Fibrinolytic treatment for elderly patients with acute myocardial infarction. Estess JM, Topol EJ, Heart 2002 87 4 308 311 10.1136/heart.87.4.308 11906993
34. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, et al. Lancet 2000 355 9215 1575 1581 10.1016/S0140-6736(00)02212-1 10821360
35. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Fox KA, Poole-Wilson P, Clayton TC, Henderson RA, Shaw TR, Wheatley DJ, Knight R, Pocock SJ, Lancet 2005 366 9489 914 920 10.1016/S0140-6736(05)67222-4 16154018
36. beta Blockade after myocardial infarction: systematic review and meta regression analysis. Freemantle N, Cleland J, Young P, Mason J, Harrison J, BMJ 1999 318 7200 1730 1737 10.1136/bmj.318.7200.1730 10381708
37. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Hulten E, Jackson JL, Douglas K, George S, Villines TC, Arch Intern Med 2006 166 17 1814 1821 10.1001/archinte.166.17.1814 17000936
38. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Keeley EC, Boura JA, Grines CL, Lancet 2003 361 9351 13 20 10.1016/S0140-6736(03)12113-7 12517460
39. Rosuvastatin in older patients with systolic heart failure. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, et al. N Engl J Med 2007 357 22 2248 2261 10.1056/NEJMoa0706201 17984166
40. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Law M, Wald N, Morris J, Health Technol Assess 2003 7 31 1 94 14670218
41. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. Nadkarni VM, Larkin GL, Peberdy MA, Carey SM, Kaye W, Mancini ME, Nichol G, Lane-Truitt T, Potts J, Ornato JP, et al. JAMA 2006 295 1 50 57 10.1001/jama.295.1.50 16391216
42. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. Oler A, Whooley MA, Oler J, Grady D, JAMA 1996 276 10 811 815 10.1001/jama.1996.03540100055028 8769591
43. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. Pignone M, Phillips C, Mulrow C, BMJ 2000 321 7267 983 986 10.1136/bmj.321.7267.983 11039962
44. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, N Engl J Med 1999 341 10 709 717 10.1056/NEJM199909023411001 10471456
45. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, et al. N Engl J Med 2005 352 12 1179 1189 10.1056/NEJMoa050522 15758000
46. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Shibata MC, Flather MD, Wang D, Eur J Heart Fail 2001 3 3 351 357 10.1016/S1388-9842(01)00144-1 11378007
47. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, Lancet 2008 372 9645 1231 1239 10.1016/S0140-6736(08) 61240-4 18757089
48. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N, Am J Med 2004 116 10 682 692 10.1016/j.amjmed.2004.01. 009 15121495
49. Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): methods and overall results. Tunstall-Pedoe H, Bailey L, Chamberlain DA, Marsden AK, Ward ME, Zideman DA, BMJ 1992 304 6838 1347 1351 10.1136/bmj.304.6838.1347 1611332
50. Effectiveness of statin therapy in adults with coronary heart disease. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, Ho M, Larsen G, McCall A, Pineros S, Sales A, Arch Intern Med 2004 164 13 1427 1436 10.1001/archinte.164.13.1427 15249352
51. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, N Engl J Med 2001 345 7 494 502 11519503
52. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R, et al. Lancet 1994 344 8922 563 570 10.1016/S0140-6736(94)91963-1 7914958
53. IMPACT Model, IMPACT Model Appendices 2007 [ http://www.liv.ac.uk/ PublicHealth/sc/bua/IMPACT-Model-%20Appendices-May-2007.pdf ]
54. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ, Circulation 2000 102 10 1126 1131 10.1161/01.CIR.102.10.1126 10973841
55. Substantial potential for reductions in coronary heart disease mortality in the UK through changes in risk factor levels. Critchley JA, Capewell S, J Epidemiol Community Health 2003 57 4 243 247 10.1136/jech.57.4.243 12646537
56. Life-years gained from coronary heart disease mortality reduction in Scotland: prevention or treatment? Critchley JA, Capewell S, Unal B, J Clin Epidemiol 2003 56 6 583 590 10.1016/S0895-4356(03)00059-3 12873654
57. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR, J Am Coll Cardiol 2002 40 9 1589 1595 10.1016/S0735-1097(02)02379-3 12427410
58. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Briggs A, Sculpher M, Buxton M, Health Econ 1994 3 2 95 104 10.1002/hec.4730030206 8044216
59. Burden of coronary heart disease in India. Gupta R, Indian Heart J 2005 57 6 632 638 16521628
60. Overweight and obesity in eastern mediterranean region: prevalence and possible causes. Musaiger AO, J Obes 2011 2011 407237 21941635
61. State Planning commission of Syrian Arab Republic, The Tenth Five Years Planning 2006-2010. Chapet 20: Heath 2006
62. Epidemiology of Type 2 diabetes mellitus in Aleppo, Syria. Albache N, Al Ali R, Rastam S, Fouad FM, Mzayek F, Maziak W, J Diabetes 2010 2 2 85 91 20923489
63. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Unal B, Critchley JA, Capewell S, Circulation 2004 109 9 1101 1107 10.1161/01.CIR.0000118498.35499.B2 14993137
64. NCDs: celebrating success, moving forward. Beaglehole R, Bonita R, Alleyne G, Horton R, Lancet 2011 378 9799 1283 1284 10.1016/S0140-6736(11)61559- 6 21982085